Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

girentuximab

A chimeric monoclonal antibody directed against G250, a cell surface antigen found in the majority of renal cell carcinomas. Following binding, girentuximab may be internalized by G250 antigen-expressing renal carcinoma cells; mAb G250 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	chimeric monoclonal antibody cG250 monoclonal antibody G-250 WX-G250
US brand name:	Rencarex
Abbreviation:	cG250 MOAB G250

girentuximab

Search NCI's Drug Dictionary